TSE:6157 stock news
This page provides real-time market news, earnings updates, and company announcements related to NS Tool Co., Ltd. (TSE:6157).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-06-29 12:41 JST
TRX News Today: Institutional Demand Drives $3.88 Trillion Crypto Boom: MoonBull, Chainlink, and Tron at the Forefront of Expansion
Bitget-RWA2025-10-28 06:12:10
Strategic token distributions and repurchase initiatives fuel sustained expansion in the crypto sector
Bitget-RWA2025-11-03 14:08:05
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Finviz2026-02-24 14:03:51
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Finviz2026-03-09 20:40:44
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Finviz2026-03-10 13:28:16
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-12 20:06:49
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Finviz2026-03-12 20:09:51
US Stock Movement | Faraday Future rises 3.5% pre-market as EAI robot business continues to deliver positive gross margin
格隆汇2026-03-13 08:24:34
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
Finviz2026-03-25 12:33:52
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Finviz2026-03-26 12:33:42
Oxbridge Highlights Strong 2025-26 Performance, Platform Expansion, and Market Opportunity; Reports Q4 and Full-Year Results
Finviz2026-03-30 20:33:43
Rigetti Announces General Availability of 108-Qubit System
Finviz2026-04-07 20:09:35
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
Microchip Expands dsPIC33A DSC Family for High-Density AI Data Center Power, Complex Motor Control and Intelligent Sensing
Finviz2026-04-14 10:18:49
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Finviz2026-03-10 13:28:16
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-12 20:06:49
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Finviz2026-03-12 20:09:51
US Stock Movement | Faraday Future rises 3.5% pre-market as EAI robot business continues to deliver positive gross margin
格隆汇2026-03-13 08:24:34
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
Finviz2026-03-25 12:33:52
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Finviz2026-03-26 12:33:42
Oxbridge Highlights Strong 2025-26 Performance, Platform Expansion, and Market Opportunity; Reports Q4 and Full-Year Results
Finviz2026-03-30 20:33:43
Rigetti Announces General Availability of 108-Qubit System
Finviz2026-04-07 20:09:35
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
Microchip Expands dsPIC33A DSC Family for High-Density AI Data Center Power, Complex Motor Control and Intelligent Sensing
Finviz2026-04-14 10:18:49
TSE:6157 stock price change
On the last trading day, TSE:6157 stock closed at 939.00 JPY, with a price change of 0.00% for the day.
Trade spot stocks (24/7)Trade stock perps (up to 100x leverage)TSE:6157 stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
To provide deeper liquidity, a more transparent trading experience, and greater capital efficiency, Bitget officially launched its all-new spot stock product, Bitget Stocks 2.0, on June 2, 2026.
The new product is independently issued by licensed RWA protocol Reality, with Bitget providing strategic support and asset security safeguards. This marks a major upgrade to the stock trading experience.
Bitget is moving stock trading beyond the limits of traditional trading models by fully integrating stock assets into its margin and yield ecosystem.
Learn more